LifeStance Q2 revenue up 24% to $259.6M; raises FY revenue guidance to $1.01-1.04B

LifeStance Health Group, Inc.

Q2 revenue $259.6M (+24% YoY); net loss $45.5M improved from $68.7M loss.
Adjusted EBITDA $14.1M (-3% YoY); Center Margin $73.0M (28.1% of revenue).
Total clinicians 6,132 (+17% YoY); net add 171 in Q2.
FY 2023 revenue guidance raised to $1.01-1.04B; reaffirms Adj. EBITDA $50-62M.
Q3 2023 guidance: revenue $250-260M, Adj. EBITDA $11-17M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

LifeStance Health Group, Inc. reported second quarter ended June 30, 2023 results: revenue $259.6 million, net income $45.5 million. Guidance raised.

Period: second quarter ended June 30, 2023
Revenue: $259.6 million
Net income: $45.5 million
Guidance: raised
Result: reported results

Exact text from the filing

the second quarter ended June 30, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q2 2023 Highlights and FY 2023 Outlook • Total revenue of $259.6 million increased $50.1 million or 24% compared to total revenue of $209.5 million • Total clinicians of 6,132 up 17%, a sequential net increase of 171 in the second quarter • Net loss

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

LifeStance Health Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.